Osaka University Venture Capital was among the investors in a series D round for Kyorin University-founded cancer treatment developer J-Pharma.
J-Pharma, a Japan-based drug development spinout of Kyorin University, has raised ¥1.8bn ($16.3m) in a series D round involving university venturing unit Osaka University Venture Capital.
Spera Pharma, a chemistry, manufacturing and controls subsidiary of drug and medical supplies producer Iwaki Group, also backed the round alongside Mizuho Capital and Mitsubishi UFJ Capital, respective VC arms of financial services firms Mizuho Bank and financial services firm Mitsubishi UFJ Financial Group.
Drug manufacturer Ohara Pharmaceutical also contributed alongside research services…
